FindTrial
Sign In

Safety and efficacy of 1-month dual antiplatelet therapy in high bleeding and ischemic risk elderly patients with coronary artery disease after implantation of zotarolimus-eluting coronary stent system (Resolute Onyx™ , Medtronic, Minneapolis, MN); A multicenter, prospective, observational study

Safety and efficacy of 1-month dual antiplatelet therapy in high bleeding and ischemic risk elderly patients with coronary artery disease after implantation of zotarolimus-eluting coronary stent system (Resolute Onyx™ , Medtronic, Minneapolis, MN); A multicenter, prospective, observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008377
Enrollment
500
Registered
2023-04-21
Start date
2022-10-26
Completion date
Unknown
Last updated
2023-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Pusan National University Yangsan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 75 years of age or older who underwent percutaneous coronary intervention using Resolute Onyx stents an aged patient.

Exclusion criteria

Exclusion criteria: - If DAPT therapy cannot be followed for a month - If additional surgery is required - If you have a non-cardiac comorbid disease with a life expectancy of less than one year - If there is a taboo against aspirin or P2Y12 inhibitors

Design outcomes

Primary

MeasureTime frame
All causes death, cardiac death, bleeding, cerebrovascular accident, stent thrombosis, myocardial infarction, target vascular failure, BARC bleeding—

Secondary

MeasureTime frame
definite or probable stent thrombosis, major bleeding Occurrence Rate—

Countries

Korea, Republic of

Contacts

Public ContactBo kyung Kim

Pusan National University Yangsan Hospital

kbk2554@naver.com+82-55-360-1453

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026